Normaloe (Loperamide Hydrochloride)

Loperamide hydrochloride acts as a peripheral μ‑opioid receptor agonist in the gastrointestinal tract. By binding to these receptors, it decreases the release of acetylcholine and other excitatory neurotransmitters, leading to reduced smooth‑muscle activity, slower gut motility, and decreased fluid secretion, which together firm up the stool.

The appropriate dose of Normaloe is determined by a qualified prescriber based on the individual’s condition, severity, age, and response to therapy. Patients should follow the healthcare professional’s instructions and not exceed the recommended amount.

Safety data for loperamide during pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using Normaloe.

To place an order, submit an enquiry on the Normaloe product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Normaloe’s active ingredient, loperamide, is a peripheral opioid that specifically reduces intestinal motility without significant central nervous system effects at recommended doses. Compared with adsorbent agents like bismuth subsalicylate, loperamide provides faster symptom control but requires caution in infectious diarrheas where slowing transit could worsen the condition.

Normaloe should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original packaging, protect them from moisture, direct sunlight, and excessive heat to maintain product stability.

Normaloe is taken orally, usually with a glass of water. The tablet should be swallowed whole and not chewed or crushed. Dosing intervals and total daily dose are set by the prescribing clinician based on the patient’s therapeutic response.

Serious risks include severe constipation that can lead to bowel obstruction, paralytic ileus, toxic megacolon in patients with certain infections, and rare cardiac arrhythmias such as QT prolongation, especially when combined with other QT‑prolonging drugs.

Normaloe should not be used by individuals with known hypersensitivity to loperamide, by patients with active infectious diarrheas caused by Clostridioides difficile or other invasive pathogens, and by those taking medications that significantly increase loperamide levels or prolong the QT interval without medical supervision.